1226847

FORM'D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

ÍOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

OMB	APPROVAL
OIAID	MINOVAL

OMB NUMBER:

3235-0076 April 30, 2008

Expires: Estimated average burden

hours per response......16.00

	SEC USE ONLY		
Prefix	Serial		
	DATÉ RECEIVED		
	1		

Name of Offering (check if this is an amendment and name has changed, and indicate change.)

Series C Convertible Preferred Stock

Filing Under (Check box(es) that apply):

☐ Rule 504

☐ Rule 505

■ Rule 506 □ Section 4(6) □ ULOE

A. BASIC IDENTIFICATION DATA

1. Enter the information requested about the issuer

Name of Issuer (check if this is an amendment and name has changed, and indicate change.)

■ Amendment

Adnexus Therapeutics, Inc.

Type of Filing: □New Filing

Address of Executive Offices

(Number and Street, City, State, Zip Code)

Telephone Number (Including Area Code)

100 Beaver Street, Suite 300, Waltham, MA 02453

Address of Principal Business Operations (if

(Number and Street, City, State, Zip Code)

Telephone Number (Including Area Code)

different from Executive Offices) Brief Description of Business:

Adnexus develops targeted medicines using a protein-therapeutic class called Adnectins.

PROCESSED

Type of Business Organization

■ corporation

□ limited partnership, already formed ☐ limited partnership, to be formed

02

other (please specify):

781-891-3745

SEP 0 7 2007

□ business trust

Actual or Estimated Date of Incorporation or Organization

Month Year

09

■ Actual

□ Estimated

THOMSON

Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State:

CN for Canada; FN for other foreign jurisdiction)

DE

FINANCIAL

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENT	IFICATION DATA		
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 					
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	■ Director	□ General and/or Managing Partner
Full Name (Last name first, if individual)					
Mendlein, John					
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
c/o Adnexus Therapeutics, Inc., 100 Be					
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Edwards, John					
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
c/o Adnexus Therapeutics, Inc., 100 Be	aver Street, Sui	te 300. Waltham, MA 0	2453		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Furfine, Eric Business or Residence Address	(Nomban and S	street, City, State, Zip Coo	10)		
business of Residence Address	(Mulliper and 2	street, City, State, Zip Cot	ie <i>)</i>		
c/o Adnexus Therapeutics, Inc., 100 Be	aver Street, Sui	te 300, Waltham, MA 0	2453		
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Bosley, Katrine					
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	le)		
/ A.B. TEL 1 100 D	6 6 .	. 200 NV-141 BEA O	3.453		
c/o Adnexus Therapeutics, Inc., 100 Ber Check Box(es) that Apply:	Promoter	Beneficial Owner	□ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	□ Floilloter	1) Belieficial Owlier	D EXECUTIVE OTHER	■ Director	Ocheran andron managing rathler
Tun ivanio (Last mano 1136, 11 marviada)					
Gage, L. Patrick					
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
c/o Adnexus Therapeutics, Inc., 100 Be	aver Street, Sui	te 300, Waltham, MA 0	2453		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Afevan. Noubar					
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
	•		•		
c/o Adnexus Therapeutics, Inc., 100 Bes					
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Nashat, Amir					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Adnexus Therapeutics, Inc., 100 Be	avor Street Sui	to 300 Waltham MA 0	7453		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)			E ENOVERTO CHING	22	
Promote Lee F					
Formela. Jean-François Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
Easiness of residence (iddiess	(1 tannooi and	Liter, Oily, Builo, Esp Co			
c/o Adnexus Therapeutics, Inc., 100 Beaver Street, Suite 300, Waltham, MA 02453					

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

A. BASIC IDENTIFICATION DATA Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Check Box(es) that Apply: □ Promoter ■ Beneficial Owner □ Executive Officer ■ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) c/o Adnexus Therapeutics, Inc., 100 Beaver Street, Suite 300, Waltham, MA 02453 Check Box(es) that Apply: □ Promoter □ Beneficial Owner □ Executive Officer Director □ General and/or Managing Partner Full Name (Last name first, if individual) Hove, Anders **Business or Residence Address** (Number and Street, City, State, Zip Code) c/o Adnexus Therapeutics, Inc., 100 Beaver Street, Suite 300, Waltham, MA 02453 Check Box(es) that Apply: □ Promoter ■ Beneficial Owner □ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) NewcoGen Group LLC Business or Residence Address (Number and Street, City, State, Zip Code) One Memorial Drive, Cambridge, MA 02140 Check Box(es) that Apply: ☐ General and/or Managing Partner □ Promoter ■ Beneficial Owner □ Executive Officer □ Director Full Name (Last name first, if individual) Rinconda LLC **Business or Residence Address** (Number and Street, City, State, Zip Code) c/o Frank Lee, Adnexus Therapeutics, Inc., 100 Beaver Street, Suite 300, Waltham, MA 02453 Check Box(es) that Apply: □ Promoter ■ Beneficial Owner □ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Polaris Venture Partners IV, L.P. **Business or Residence Address** (Number and Street, City, State, Zip Code) 1000 Winter Street, Suite 3350, Waltham, MA 02451 Check Box(es) that Apply: □ Director □ Promoter ■ Beneficial Owner □ Executive Officer ☐ General and/or Managing Partner Full Name (Last name first, if individual) Applied Genomic Technology Capital Fund, L.P. **Business or Residence Address** (Number and Street, City, State, Zip Code) One Memorial Drive, Cambridge, MA 02140 Check Box(es) that Apply: □ Promoter ■ Beneficial Owner □ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Atlas Venture Fund V, L.P. Business or Residence Address (Number and Street, City, State, Zip Code) 890 Winter Street, Suite 320, Waltham, MA 02451 Check Box(es) that Apply: □ Promoter ■ Beneficial Owner □ Executive Officer □ Director □ General and/or Managing Partner Full Name (Last name first, if individual) Atlas Venture Fund VI, L.P. **Business or Residence Address** (Number and Street, City, State, Zip Code) 890 Winter Street, Suite 320, Waltham, MA 02451

890 Winter Street, Suite 320, Waltham, MA 02451
Check Box(es) that Apply:

Full Name (Last name first, if individual)

■ Beneficial Owner

☐ Executive Officer

□ Director

☐ General and/or Managing Partner

Venrock Associates IV, L.P.

Business or Residence Address (Number and Street, City, State, Zip Code)

1

30 Rockefeller Plaza, Room 5508, New York, NY 10112

	B. INFORMATION ABOUT OFFERING		
		Yes	No
l.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?		•
2.	What is the minimum investment that will be accepted from any individual?	\$n/a	
		Yes	No
3.	Does the offering permit joint ownership of a single unit?	•	
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.		
Full Non	Name (Last name first, if individual)		
	iness or Residence Address (Number and Street, City, State, Zip Code)		
15434	mas of residence reariss (trained and buses, exp, eace, exp editor)		
Nan	ne of Associated Broker or Dealer		***
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)	All States	
] _ [AL} _ [AK] _ [AZ] _ [AR] _ [CA] _ [CO] _ [CT] _ [DE] _ [DC] _ [FL] _ [GA] IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK] RI] _ [SC] _ [SD] _ [TN] _ [TX] _ [UT] _ [VT] _ [VA] _ [WA] _ [WV] _ [WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
	name (Last name first, if individual)	_ [,, ,]	_ [++/]
1 411	manie (2001 name 1151, il morridani)		
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
] _ [AL] _ [AK] _ [AZ] _ [AR] _ [CA] _ [CO] _ [CT] _ [DE] _ [DC] _ [FL] _ [GA] !L] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK] RI] _ [SC] _ [SD] _ [TN] _ [TX] _ [UT] _ [VT] _ [VA] _ [WA] _ [WV] _ [WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	Name (Last name first, if individual)		
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)		
Nan	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
] _] _	AL] _[AK] _[AZ] _[AR] _[CA] _[CO] _[CT] _[DE] _[DC] _[FL] _[GA] IL] _[IN] _[IA] _[KS] _[KY] _[LA] _[ME] _[MD] _[MA] _[MI] _[MN] MT] _[NE] _[NV] _[NH] _[NJ] _[NM] _[NY] _[NC] _[ND] _[OH] _[OK] RI] _[SC] _[SD] _[TN] _[TX] _[UT] _[VT] _[VA] _[WA] _[WV] _[WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ {ID] _ [MO] _ [PA] _ [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box pand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	s	s
	Equity	\$ <u>15,910,166</u>	\$ <u>15,910,166</u>
	□ Common ■ Preferred		
	Convertible Securities (including warrants)	s	s
	Partnership Interests	\$	s
	•	s	s
	Other (Specify)		
	Total	\$ <u>15,910,166</u>	\$ <u>15,910,166</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	19	\$ <u>15,910,166</u>
	Non-accredited Investors		•
	Total (for filings under Rule 504 only).		2
			2
	Answer also in Appendix, Column 4, if filing under ULOE		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. Type of offering Rule 505	Type of Security	Dollar Amount Sold S S
	Rule 504		\$
	Total		s
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		s
	Printing and Engraving Costs	0	s
	Legal Fees	-	S 70,000
	Accounting Fees	_	\$
	Engineering Fees.		\$
	Sales Commissions (specify finders' fees separately)	0	s
	Other Expenses (identify)	0	\$
	Total	■	\$ 70,000
		=	

	C. OFFERING PRICE, NUMBER OF INVESTORS, EX	PENSES AN	D ÚSE OF PROCEEDS		
	 Enter the difference between the aggregate offering price given in response to Part C – t and total expenses furnished in response to Part C – Question 4.a. This difference is the "adjusted gross proceeds to the issuer." 			s.	15,840,166
i.	Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to for each of the purposes shown. If the amount for any purpose is not known, furnish an es and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C – Question 4.b above,	timate			
			Payments to Officers, Directors, & Affiliates		Payments To Others
	Salaries and fees	E)	\$ <u></u>	o	\$
	Purchase of real estate	ø	S	0	\$
	Purchase, rental or leasing and installation of machinery and equipment	O	\$	D	s
	Construction or leasing of plant buildings and facilities	ø	2		\$
	Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a				
	merger)	ם	22	ם	\$
	Repayment of indebtedness		\$	0	S
	Working capital	a	<u> </u>	=	\$ 15,840,166
	Other (specify):	o	S	0	s
			S		ę.
	Column Totals.	_	6 0		\$ 15,840,166
		•	# <u></u>	=	
	Total Phyments Listed (column totals added)		■ \$ <u>15</u>	<u>,840,166</u>	-

D. FEDERAL SIGNATURE

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type) Adnexus Therapeutics, Inc.	Signature	Date August 22 2007	
Name of Signer (Print or Type) John D. Mendlein	Title of Signer (Print or Type) President and Chief Executive Officer		

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

